Cantor Fitzgerald raised the firm’s price target on Belite Bio (BLTE) to $266 from $200 and keeps an Overweight rating on the shares. Recent commentary suggested a possibility of a much higher WAC than the $200K/year the firm was modeling, the analyst tells investors in a research note.

Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions

Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on BLTE:

Disclaimer & DisclosureReport an Issue

Belite Bio price target raised to $201 from $191 at Morgan Stanley

Belite Bio price target raised to $200 from $195 at BofA

Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target

Midday Fly By: Markets bounce back following U.S.-Israeli attacks on Iran

Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win